The United States Department of Justice filed a complaint in Boston federal court today, alleging that pharmaceutical manufacturer Johnson & Johnson committed Medicaid fraud by paying Omnicare pharmacies kickbacks for recommending that nursing home patients use Risperdal® and other Johnson & Johnson drugs. Omnicare is the largest pharmacy supplying drugs to nursing homes in the United States. The kickback scheme had originally been reported by a Chicago pharmacist whistleblower, who was fired by Omnicare after reporting the scheme. The government's action came in a "qui tam" suit filed for the whistleblower, Bernard Lisitza, under the False Claims Act by Chicago lawyers Michael Behn and Linda Wyetzner of Behn & Wyetzner, Chartered. The False Claims Act allows private citizens with knowledge of fraud (called "relators") to help the government recover ill-gotten gains.
Boston, MA (PRWEB) January 15, 2009 -- The United States Department of Justice joined a whistleblower case today, alleging in Boston federal court, that pharmaceutical manufacturer Johnson & Johnson paid kickbacks to increase sales of its drugs, such the anti-psychotic Risperdal®, to elderly patients on Medicaid. (No. 07-10288-RGS) According to the government's complaint, Johnson & Johnson paid tens of millions of dollars in kickbacks to Omnicare, the nation's largest pharmacy for nursing homes. The government's case against Johnson & Johnson was initiated by a Chicago pharmacist, Bernard Lisitza, who was fired by Omnicare after he challenged the Risperdal® kickbacks and other improper practices. On November 3, 2009, Omnicare paid $98 million to settle Lisitza's allegations concerning Johnson & Johnson's Risperdal® p
Copyright©2010 Vocus, Inc.
All rights reserved